Kodiak Sciences (KOD): Why the FunStock Gauges Keep Running After You Buy

A 246% Gain, a Phase 3 Breakthrough—and a Powerful Lesson in Following Great Investors

Baker Bros. put KOD on our radar. Institutions accumulated. Shorts piled in. The losses continued. Then the science delivered.

 

📌 “ Find the signal. Understand why it matters. Make your decision. Then keep watching every gauge that could prove your thesis right—or prove it wrong.” — FUNanc1al 

There is a temptation in investing to think the research ends when you click Buy.

We think almost the opposite.

Buying is not the end of the research. It is the beginning of the monitoring.

Kodiak Sciences (Nasdaq: KOD) offers a fascinating case study.

Back in December 2025, FUNanc1al published a cautiously bullish analysis of Kodiak after specialist biotech investor Baker Bros. Advisors made a major additional investment in the company.

Kodiak was trading around $26 per share when we published.

On September 28, 2026, Kodiak announced successful pivotal Phase 3 results for two experimental treatments for wet age-related macular degeneration. Both Zenkuda and KSI-501—now also called tabirafusp-ted—met their primary endpoints. Zenkuda was particularly notable: 54% of patients successfully achieved 6-month dosing durability at year one while maintaining visual gains and retinal drying. Kodiak plans to submit a Biologics License Application for Zenkuda in the fourth quarter of 2026.

The market's reaction was extraordinary.

KOD surged approximately 178% in a single trading session, closing at $89.92.

From roughly $26 when we published our original analysis, that's approximately a 246% gain—or about 3.5× the original value.

Wonderful.

But that's not actually the most interesting part of the story.

The more useful lesson is what happened between December and September.

Because several of the gauges behind our FunStock methodology kept moving.

And they were telling a fascinating story.

📈 Gauge #1: Follow the Great Investors—Then Keep Watching

Our original interest in Kodiak wasn't based on a stock chart.

It was partly triggered by Baker Bros. Advisors, one of the best-known specialist biotechnology investors.

In December 2025, Baker-affiliated funds purchased approximately 2.61 million additional Kodiak shares at $23 each, an investment of roughly $60 million. SEC filings confirm the transaction. Baker Bros. was already a major Kodiak shareholder.

That didn't make Kodiak a guaranteed winner.

Nothing does.

But when a highly specialized investor with deep knowledge of biotechnology commits that much additional capital, we think it's worth asking:

What do they see?

That's the first lesson.

But here's the second.

Don't stop watching after you invest.

At the time of our original analysis, institutional ownership was already substantial. Over the ensuing months, reported institutional participation expanded further.

That doesn't prove Baker Bros. caused other institutions to buy. Institutional filings are delayed, ownership databases use different methodologies, and figures above 100% of float can arise because of timing differences, short selling, lending and differing definitions of float.

So we should not overinterpret a single percentage.

But the direction is worth monitoring.

A specialist investor made a major commitment.

And institutional participation remained extraordinarily strong.

The signal didn't disappear after our original article. It evolved.

🐻 Gauge #2: Meanwhile, the Shorts Were Moving the Other Way

Here's where the story becomes even more interesting.

Short interest also climbed dramatically.

Around the time of our December article, roughly 8.3% of Kodiak's float was sold short.

By July 15, 2026, short interest had risen to approximately 18.0% of the float, with a short ratio—or days to cover—of approximately 14 days.

Think about that combination.

You had sophisticated long investors maintaining substantial exposure.

And simultaneously, a growing population of investors betting against the company.

Someone was going to be very wrong.

That disagreement itself was information.

A days-to-cover figure around 14 also meant that, if sufficiently powerful positive news arrived, short sellers could face considerable pressure to repurchase shares.

Then came September 28.

Kodiak announced that both Zenkuda and tabirafusp-ted met their primary endpoints in the pivotal Phase 3 DAYBREAK trial in wet AMD. Zenkuda demonstrated non-inferior vision gains compared with aflibercept, and 54% of patients achieved six-month durability at year one under the trial's retreatment criteria.

KOD exploded higher.

Can we say the approximately 178% move was caused by a short squeeze?

No.

The fundamental catalyst was unmistakably the clinical data.

But with short interest near 18% of float in the preceding months and a roughly 14-day short ratio, short covering could plausibly have amplified the move.

That's precisely why short interest belongs on the dashboard.

🧪 Gauge #3: The Financials Still Looked Like Biotech Financials

And then there was the income statement.

Kodiak reported its second-quarter 2026 results in August.

They weren't exactly the numbers you'd expect from Coca-Cola.

Q2 2026:

• Net loss: $65.6 million

• Loss per share: $1.05

• R&D expense: $56.1 million

• Cash and cash equivalents at quarter-end: $125.9 million

R&D expense had increased from $42.8 million a year earlier as Kodiak funded its late-stage clinical programs and manufacturing activities.

In other words:

Business as usual for a clinical-stage biotech.

No meaningful commercial revenue.

Large research expenses.

Continuing losses.

Cash burn.

Regulatory uncertainty.

Clinical-trial risk.

Those weren't bugs in the analysis.

They were the reason our original conclusion was cautiously bullish, rather than simply bullish.

And they also help explain why sophisticated investors could reach dramatically different conclusions about the stock.

The bears saw losses, cash consumption, execution risk and a company whose valuation ultimately depended on experimental medicines.

They weren't irrational.

But biotechnology has an unusual characteristic:

The income statement can look terrible while the underlying science is becoming dramatically more valuable.

And sometimes the science wins.

🔬 Then the Most Important Gauge Moved: The Science

Ultimately, Baker Bros. didn't make DAYBREAK succeed.

Institutional ownership didn't make it succeed.

Short interest certainly didn't make it succeed.

The drugs had to work.

On September 28, Kodiak reported that Zenkuda and tabirafusp-ted achieved their primary endpoints in DAYBREAK.

Zenkuda demonstrated non-inferior vision gains compared with aflibercept while potentially allowing substantially longer intervals between injections for many patients.

More than half—54%—were maintained on a six-month dosing interval at year one under the study's retreatment criteria. Kodiak said it plans to submit a multi-indication BLA for Zenkuda in the fourth quarter of 2026.

For patients facing repeated injections into the eye to control a disease capable of destroying central vision, durability matters.

For investors, so does the commercial implication.

And suddenly the market had to reprice Kodiak.

Fast.

🧭 The FunStock Lesson: Never Turn Off the Dashboard

This is why we don't believe investment analysis should end with a recommendation—or with a purchase.

Imagine buying Kodiak after reading our December article and then continuing to monitor the gauges.

You would have watched:

Specialist investors: Baker Bros. had committed roughly another $60 million.

Institutions: institutional participation remained exceptionally high and broadened according to ownership databases.

Short sellers: bearish positioning roughly doubled from December levels, eventually approaching 18% of float.

Financials: losses and R&D spending continued, reinforcing the speculative nature of the investment.

Cash: Kodiak ended Q2 with $125.9 million, with management saying existing cash was expected to support planned operations into 2027.

Catalysts: pivotal Phase 3 results were approaching.

And finally:

Science: DAYBREAK delivered.

No individual gauge could tell you what would happen.

Together, however, they provided a much richer picture of the evolving risk/reward equation.

That is exactly what the FunStock methodology is intended to do.

⚠️ Signals Are Not Guarantees

There's an important warning embedded in this success story.

Suppose DAYBREAK had failed.

Kodiak could have moved violently in the opposite direction.

Baker Bros. could have been wrong.

Institutions could have been wrong.

We could have been wrong.

That's biotechnology.

And even after successful Phase 3 results, important questions remain. Regulatory approval is not guaranteed. Commercial adoption is not guaranteed. Competitors don't disappear. Manufacturing matters. Pricing matters. Reimbursement matters. Additional capital could eventually be required.

A stock that has risen approximately 178% in one session also presents a very different valuation and risk/reward proposition from the stock we examined around $26.

Yesterday's signal is not automatically today's opportunity.

That's another reason to keep the dashboard running.

💡 Following the Best Is a Starting Point, Not a Strategy

Perhaps that's the biggest lesson from Kodiak.

We track great investors because expertise matters.

We track insiders because capital committed by people close to a business can matter.

We track institutions because large changes in ownership can reveal where professional capital is moving.

We track shorts because they force us to confront the opposing thesis.

We track earnings because companies ultimately need financial resources to execute and grow.

We track catalysts because markets reprice information.

And in biotechnology, above everything else, we track the science.

None of those gauges predicts the future.

But together, they can help us ask better questions.

And occasionally, they can lead us somewhere extraordinary.

From roughly $26 to $89.92 in nine months certainly qualifies.

But the lesson isn't:

“We found a stock that tripled.”

The better lesson is:

Find the signal. Understand why it matters. Make your decision. Then keep watching every gauge that could prove your thesis right—or prove it wrong.

Investing doesn't stop when you buy.

That's when the next chapter begins.

Food for thought.

Carpe diem.